Thursday, February 5, 2026

Medication Adherence among Drug-Resistant Tuberculosis Patients at UI Hospital

Who

The study involved 87 drug-resistant tuberculosis (DR-TB) patients aged 18 years or older who were receiving treatment and attending routine monthly follow-up visits at Universitas Indonesia Hospital. Most participants were male and aged 18–59 years.


What

The study assessed medication adherence levels among DR-TB patients. Results showed that 50.6% of patients had low adherence, 47.1% moderate adherence, and only 2.3% high adherence. Adherence was significantly associated with gender, and tended to be higher among females, patients aged 18–59 years, those with secondary education, new TB cases, and patients receiving long-term treatment regimens.


When

The study was conducted between February and March 2024.


Where

The research took place at Universitas Indonesia Hospital in Depok City, Indonesia.


Why

The study aimed to evaluate treatment adherence among DR-TB patients, as poor adherence can compromise treatment effectiveness, prolong therapy, and increase the risk of poor clinical outcomes in DR-TB management.


How

An observational cross-sectional study design was used. Data were collected using the validated Indonesian version of the Morisky Medication Adherence Scale (MMAS-8). Adherence scores were classified into low (<6), moderate (6 to <8), and high (8). Associations between patient characteristics and adherence levels were analyzed.

Source: Harahap, D.W.S., Andrajati, R., Sari, S.P. and Handayani, D., 2024. Medication Adherence among Drug-Resistant Tuberculosis (DR-TB) Patients at Universitas Indonesia Hospital. Jurnal Respirologi Indonesia, 44(3), pp.196-200.

The association between TB–HIV coinfection and DR-TB treatment failure

Who

The study included 4,261 drug-resistant tuberculosis (DR-TB) patients aged 15 years or older who were diagnosed, treated, and recorded in the Indonesian Tuberculosis Information System (SITB) during 2022–2023. Among them, 153 patients had TB–HIV coinfection and 4,108 did not. Patients who were lost to follow-up (1,051 cases) were excluded.


What

The study examined the association between TB–HIV coinfection and DR-TB treatment failure. The findings showed that TB–HIV coinfection was significantly associated with a higher risk of treatment failure. After adjusting for age, patients with TB–HIV coinfection had a 2.3 times higher risk of DR-TB treatment failure compared with patients without TB–HIV coinfection.


When

Data were collected from the 2022–2023 SITB database, with treatment outcomes evaluated up to 2023, accounting for the long duration of DR-TB treatment (up to 20 months).


Where

The study was conducted in Indonesia, using nationwide data from the Indonesian Tuberculosis Information System (SITB).


Why

The research aimed to address the limited evidence on whether TB–HIV coinfection contributes to DR-TB treatment failure in Indonesia, while controlling for important confounding factors such as age, TB–DM coinfection, sex, and type of anti-tuberculosis drug regimen.


How

An observational analytic retrospective cohort design was used with secondary data from SITB. DR-TB diagnosis was based on Xpert MTB/RIF testing. HIV status was determined using HIV rapid tests, and TB–DM coinfection was assessed using rapid blood glucose tests. Treatment outcomes were categorized into treatment failure and treatment success. Statistical analyses included bivariate analysis, stratified analysis, homogeneity testing, and multivariable logistic regression to identify confounders and calculate adjusted odds ratios (AORs).

Source: Laili, F., Ronoatmodjo, S. and Murtiani, F., 2024. Ko-Infeksi TB-HIV terhadap Kegagalan Pengobatan Pasien Tuberkulosis Resistan Obat di Indonesia. The Indonesian Journal of Infectious Diseases, 10(2), pp.153-165.

Wednesday, February 4, 2026

The potential effect of a geographically focused intervention against TB in the USA

Who

  • Study population: People aged ≥15 years diagnosed with tuberculosis (TB) in the USA.

  • Data source: National TB Surveillance System (NTSS).

  • Time period: 2011–2019.

  • Key subgroups: Racially and ethnically minoritised populations (Black, Hispanic, Asian, American Indian or Alaska Native [AIAN], and other non-White groups).

  • Exclusions: People incarcerated at TB diagnosis (3.9% of racially minoritised cases).

  • Intervention-eligible groups: People born outside the USA, people living with HIV, and people experiencing homelessness.


What

  • Objective: To estimate the health impact, cost, cost-effectiveness, and equity effects of a one-time targeted latent tuberculosis infection (LTBI) testing and treatment intervention.

  • Key findings:

    • Targeting the top 5% of US counties with the highest TB risk among racially minoritised populations captured 47.4% of all TB cases.

    • The intervention was estimated to avert:

      • 17,359 TB cases

      • 2,700 TB deaths

      • 14,951 QALYs gained over participants’ lifetimes.

    • 94.1% of people with LTBI in intervention counties were racially minoritised.

    • The intervention reduced TB incidence across most racial and ethnic groups and modestly reduced racial and ethnic disparities, especially for Black people.

    • Cost-effectiveness: $86,177 per QALY gained (2022 USD).


When

  • TB surveillance data: 2011–2019.

  • Projection period for impact on incidence and disparities: 2026–2040.

  • Post-2020 data excluded due to COVID-19–related disruptions in TB diagnosis.


Where

  • Geographic scope: All 50 US states and the District of Columbia.

  • Intervention focus: 157 counties (top 5% by a TB risk score combining TB incidence among racially minoritised people and their population share).


Why

  • Rationale: TB incidence remains disproportionately high among racially and ethnically minoritised populations in the USA.

  • Policy challenge: Current US guidelines do not allow LTBI testing to be restricted by race or ethnicity, necessitating a strategy that:

    • Reduces disparities,

    • Maximizes population health impact,

    • Remains guideline-concordant and cost-effective.

  • Goal: Inform resource allocation and decision making for TB elimination efforts.


How

  • Design: Modeling study combining surveillance data, statistical smoothing, and economic simulation.

  • Targeting approach:

    1. County-level targeting: Selected counties with highest TB burden among racially minoritised populations.

    2. Individual-level targeting: Offered LTBI testing to all people with guideline-recommended risk factors, regardless of race or ethnicity.

  • LTBI estimation: Back-calculated from TB incidence using published reactivation rates and spatially smoothed generalized additive models.

  • Intervention: Interferon gamma release assay testing, followed by 3 months of weekly isoniazid plus rifapentine.

  • Analysis:

    • Markov cohort model for lifetime health and economic outcomes.

    • Incremental cost-effectiveness ratios (ICERs) estimated from a TB health services perspective.

    • Quasi-Poisson models projected future TB incidence and disparities.

  • Oversight: Analysis of de-identified surveillance data reviewed by the Centers for Disease Control and Prevention, classified as research not involving human participants.


Overall conclusion

A geographically focused, guideline-concordant LTBI testing and treatment intervention could produce substantial health gains, be moderately cost-effective, and achieve small but meaningful reductions in racial and ethnic TB disparities, supporting its use as a strategic tool for TB elimination in the USA.

Source: Regan, M., Cui, H., Swartwood, N.A., Li, Y., Marks, S.M., Barham, T., Khan, A., Winston, C.A., Cohen, T., Horsburgh, C.R. and Salomon, J.A., 2026. The potential effect of a geographically focused intervention against tuberculosis in the USA: a simulation modelling study. The Lancet Public Health, 11(2), pp.e82-e91.

Monday, February 2, 2026

Socioeconomic Burden, Stigma, and Prevention Strategies in Tuberculosis

The financial consequences of tuberculosis (TB) are broadly classified into direct and indirect costs. Direct costs include medical expenses such as drugs, laboratory tests, physician fees, radiological investigations, and hospitalization. These costs are often high relative to per capita income and place a substantial burden on household finances, particularly in low- and middle-income countries. Indirect costs arise from illness-related loss of income, reduced work capacity, and decreased labor supply due to disability or death. TB also imposes significant pressure on healthcare systems through increased hospital expenditures and welfare costs, although potential revenues could be generated through effective cost recovery for services such as diagnostics, drugs, radiology, and human resources.

Tuberculosis remains highly stigmatized in many communities, primarily due to fear of transmission, but also because of its strong association with HIV, poverty, low social status, malnutrition, and socially disapproved behaviors. This stigma can lead to social isolation, abandonment by family, exclusion from workplaces or communities, and job loss. Negative and often poorly informed societal perceptions reinforce discrimination against TB patients. Because TB has long been associated with poverty, poor hygiene, and social marginalization, affected individuals may face social disregard. Limited awareness and misinformation contribute significantly to this prejudice, and in some cases, stigma within healthcare settings further compromises access to diagnosis, treatment adherence, and clinical outcomes.

Tuberculosis and malnutrition are closely linked, with malnutrition acting both as a risk factor for infection and as a consequence of disease. Malnutrition is associated with poorer prognosis, increased mortality, and false-negative tuberculin test results, which may delay diagnosis. Nutritional deficiencies can cause secondary immunodeficiency, increasing susceptibility to TB. Conversely, TB reduces appetite, impairs nutrient absorption, alters metabolism, and leads to muscle wasting due to impaired protein utilization. Deficiencies in micronutrients such as zinc, selenium, iron, copper, and vitamins A, C, D, and E further compromise immune function. Low serum vitamin D levels have been observed in patients with active TB and multidrug-resistant TB during treatment. Improving nutritional status and providing adequate supplementation may support recovery and represent an effective strategy for TB control in resource-limited settings.

Since the introduction of antibiotics in the 1940s, tuberculosis has become a treatable disease. Current TB elimination strategies focus on early detection and treatment of active cases to interrupt transmission, alongside screening and treatment of latent TB infection to prevent disease progression.

Bacillus Calmette-Guérin (BCG) vaccination is the most widely administered vaccine worldwide and provides protection against severe forms of TB in young children, particularly miliary and disseminated disease. However, it does not consistently protect against pulmonary TB.

To improve adherence in the treatment of latent TB infection, the World Health Organization has recommended since 2020 a three-month regimen of weekly rifapentine and isoniazid (3HP).

Close contact remains an important route of TB transmission. Even routine parental behaviors such as kissing children may pose a risk when caregivers are infected, highlighting the need for awareness and preventive caution.

Following the introduction of X-rays in 1895, chest radiography became an essential tool for identifying pulmonary TB lesions. From the 1940s onward, radiographic screening enabled earlier detection of active disease, including cases without overt clinical symptoms, allowing timely initiation of treatment and improved disease control.

Source: Varotto, E., Martini, M., Vaccarezza, M., Vittori, V., Mietlińska-Sauter, J., Gelsi, R., Galassi, F.M. and Papa, V., 2025. Historical and Social Considerations upon Tuberculosis. Journal of Preventive Medicine and Hygiene, 66(1), pp.E145-E152.

Medication Adherence among Drug-Resistant Tuberculosis Patients at UI Hospital

Who The study involved 87 drug-resistant tuberculosis (DR-TB) patients aged 18 years or older who were receiving treatment and attending ...